LRG1 Protein, Cynomolgus, Recombinant (His)

Catalog No. TMPK-00526

Diabetic nephropathy (DN) is an important public health concern of increasing proportions and the leading cause of end-stage renal disease (ESRD) in diabetic patients. It is one of the most common long-term microvascular complications of diabetes mellitus that is characterized by proteinuria and glomerular structural changes. LRG1 is a novel pro-angiogenic factors involved in the abnormal angiogenesis and renal fibrosis in DN. LRG1 Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 35.69 kDa and the accession number is A0A2K5VVA4.

LRG1 Protein, Cynomolgus, Recombinant (His)

Catalog No. TMPK-00526

Pack Size	Price	Availability
100 μg	$487	7-10 days
500 μg	$1,950	7-10 days
1 mg	$3,250	7-10 days

Bulk & Custom

Add to Cart

Questions

Resource Download

User Guide of Recombinant Proteins

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Information

Biological Activity	Immobilized Cynomolgus LRG1, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Anti-LRG1 Antibody, hFc Tag with the EC50 of 0.14μg/ml determined by ELISA.
Description	Diabetic nephropathy (DN) is an important public health concern of increasing proportions and the leading cause of end-stage renal disease (ESRD) in diabetic patients. It is one of the most common long-term microvascular complications of diabetes mellitus that is characterized by proteinuria and glomerular structural changes. LRG1 is a novel pro-angiogenic factors involved in the abnormal angiogenesis and renal fibrosis in DN. LRG1 Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 35.69 kDa and the accession number is A0A2K5VVA4.
Species	Cynomolgus
Expression System	HEK293 Cells
Tag	C-His
Accession Number	A0A2K5VVA4
Synonyms	LRG1,LRG,Leucine-rich α-2-glycoprotein,Leucine-rich alpha-2-glycoprotein
Construction	Val72-Gln383
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Molecular Weight	35.69 kDa (predicted). Due to glycosylation, the protein migrates to 50-60 kDa based on Tris-Bis PAGE result.
Endotoxin	< 1 EU/μg by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.
Reconstitution	Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice.
Research Background	Diabetic nephropathy (DN) is an important public health concern of increasing proportions and the leading cause of end-stage renal disease (ESRD) in diabetic patients. It is one of the most common long-term microvascular complications of diabetes mellitus that is characterized by proteinuria and glomerular structural changes. LRG1 is a novel pro-angiogenic factors involved in the abnormal angiogenesis and renal fibrosis in DN.